ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2015013861
pages 315-327

Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology

Rimas J. Orentas
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Crystal L. Mackall
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

要約

After decades of basic research, immune-based therapeutics for the treatment of cancer are showing evidence of efficacy in clinical trials; several immunotherapeutics already incorporated into standard treatment regimens. Intensive research is underway to improve the efficacy of immunotherapeutics and to expand the application of immunotherapy to a wider array of cancers. The therapeutic options that comprise immunotherapy for cancer are vast and span monoclonal antibodies, tumor vaccines, adoptive cellular therapies, as well as therapies aimed at reversing immunosuppression and enhancing immune reactivity globally and/or locally within the tumor microenvironment. In pediatric cancer, monoclonal antibodies have demonstrated efficacy in hematologic malignancies, and neuroblastoma and bispecific antibodies that activate resident T cells, as well as adoptive cell therapy, have shown recent exciting results for the treatment of acute lymphoblastic leukemia in childhood. This review discusses the basic principles of tumor immunology driving clinical development of new immunotherapies, describes immunotherapeutics with demonstrated efficacy and several currently in clinical trials, and highlight agents that seem to be most promising for the treatment of pediatric cancer.


Articles with similar content:

Immunotherapeutic Approaches to Head and Neck Cancer
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Hassan Nasser, Maie St. John
Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Phillip A. Abarca, Caitlin Marx, Jennifer L. Strunck, Catherine Neumann, Kevin Y. Kim, Brian Wolf, Robert M. Elashoff, Edward B. Garon, Danielle Nameth
Recent Advances in Cancer Stem Cell Targeted Therapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Muge Ocal, Hakan Akbulut, Samira Abdi Abgarmi, Merve Besler, Cansu Babahan
Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma
Critical Reviews™ in Biomedical Engineering, Vol.40, 2012, issue 4
Frank O. Nestle, Louise Saul, Sophia N. Karagiannis, Sophia Tsoka, Debra H. Josephs, Chrysanthi Ainali, Panagiotis Karagiannis
Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu